title: New drugs for HDL-C disorders: the beginning.
abstract: For more than 20 years there has been increasing interest in the development of novel therapies to raise levels of high-density lipoprotein cholesterol (HDL-C). However, well publicized failures of recent clinical trials of agents that raise HDL-C levels have stimulated considerable controversy with regard to the potential clinical utility of this therapeutic target. A number of classes of agents are currently under investigation with variable effects on HDL quantity and quality. These will be reviewed.
authors.forename: MyNgan
authors.initials: M
authors.lastname: Duong
authors.affiliation: South Australian Health and Medical Research Institute. PO Box 11060. Adelaide, SA, 5001, Australia. stephen.nicholls@sahmri.com.
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Nicholls
mesh_terms: D000818:Animals; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors; D008076:Cholesterol, HDL / Q000097:blood*; D006801:Humans; D009525:Niacin / Q000378:metabolism
chemical_list: D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL; D009525:Niacin